Comparing Gain Therapeutics (NASDAQ:GANX) & Reviva Pharmaceuticals (NASDAQ:RVPH)

Gain Therapeutics (NASDAQ:GANX) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings and Valuation

This table compares Gain Therapeutics and Reviva Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50,000.00	1,518.34	-$20.16 million	($0.58)	-3.07
Reviva Pharmaceuticals	N/A	N/A	-$19.86 million	($4.06)	-0.10

Reviva Pharmaceuticals has lower revenue, but higher earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gain Therapeutics and Reviva Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

Insider & Institutional Ownership

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Gain Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Gain Therapeutics and Reviva Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1	0	4	0	2.60
Reviva Pharmaceuticals	1	2	5	0	2.50

Gain Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 377.53%. Reviva Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 16,042.05%. Given Reviva Pharmaceuticals’ higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Gain Therapeutics.

Summary

Reviva Pharmaceuticals beats Gain Therapeutics on 8 of the 12 factors compared between the two stocks.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.